HKIMG
VRTX icon

Hutchens & Kramer Investment Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Hutchens & Kramer Investment Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-457
Closed -$207K – 196
2025
Q4 		$207K Buy
+457
New +$197K 0.07% 166

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hutchens & Kramer Investment Management Group's VRTX Position: Q1 2026 in Review

Hutchens & Kramer Investment Management Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 457 shares — an estimated $207K sold.

Hutchens & Kramer Investment Management Group first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $207K in Q4 2025. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Hutchens & Kramer Investment Management Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hutchens & Kramer Investment Management Group sold 457 Vertex Pharmaceuticals shares in Q1 2026, an estimated $207K.
  • Hutchens & Kramer Investment Management Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Hutchens & Kramer Investment Management Group's Vertex Pharmaceuticals position peaked at $207K in Q4 2025.
  • 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hutchens & Kramer Investment Management Group's 13F filing for Q1 2026, filed 15 Apr 2026.